Clearside Biomedical, Inc.
CLSD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $70 | $72 | $67 | $161 |
| - Cash | $20 | $29 | $48 | $30 |
| + Debt | $52 | $43 | $35 | $1 |
| Enterprise Value | $103 | $86 | $54 | $131 |
| Revenue | $2 | $8 | $1 | $30 |
| % Growth | -79.8% | 519.9% | -95.5% | – |
| Gross Profit | $2 | $8 | $1 | $30 |
| % Margin | 91% | 95.7% | 84.6% | 100% |
| EBITDA | -$24 | -$23 | -$29 | $1 |
| % Margin | -1,463.2% | -280.3% | -2,220.3% | 1.9% |
| Net Income | -$34 | -$32 | -$33 | $0 |
| % Margin | -2,064.4% | -394.9% | -2,482.8% | 1.3% |
| EPS Diluted | -7.05 | -7.95 | -8.25 | 0.095 |
| % Growth | 11.3% | 3.6% | -8,830.2% | – |
| Operating Cash Flow | -$25 | -$18 | -$13 | -$11 |
| Capital Expenditures | -$1 | -$2 | -$0 | $0 |
| Free Cash Flow | -$26 | -$20 | -$14 | -$11 |